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Background:  Granulocyte  colony  stimulating  factor (G-CSF)  improves  the  survival  of animals  with  myocar-
dial infarction  by  inducing  bone  marrow  stem  cell  mobilization  and  homing  to infarcted  areas.  However,
its  precise  mechanisms  and  direct  effects  on  the  ischemic  myocardium  remain  unclear.  In  this  study  we
investigated  the direct  effects  and  mechanisms  of G-CSF  in  a rabbit  model  of  chronic  myocardial  ischemia.
Methods:  Myocardial  ischemia  models  were  created  by  partial  ligation  of  the  left anterior  descending
coronary  artery  in  Japanese  white  male  rabbits.  Rabbits  were  subcutaneously  injected  with  10  g/kg of
G-CSF  (G-CSF  group)  or saline  (control  group)  for 6 days  after  myocardial  ischemia.  Direct effects  of G-CSF
were  analyzed  by  immunohistochemistry  and  terminal  dUTP  nick  end-labeling  (TUNEL).
Results:  Rabbits  in  the  G-CSF  group  exhibited  75% survival  compared  to  40%  in  the  control  group  (p <  0.05).
Immunohistochemistry  of  the  ischemic  myocardium  showed  increased  homing  of CD34+  cells  on  day  7
post-surgery  and  more  vessels  on  day  28 post-surgery  by  anti-von  Willebrand  factor  staining  in the
G-CSF  group  compared  with the  control  group.  Furthermore,  an  increased  percentage  of  CD34+  cells
were  observed  in  peripheral  blood  and  upregulation  of  vascular  endothelial  growth  factor  expression  in
ischemic  tissue  in  the  G-CSF  group  compared  with  the  control  group.  TUNEL  showed  that  the apoptotic
index  in  the  ischemic  myocardium  decreased  in the G-CSF  group  compared  with  the control  group  on
day  28 post-surgery.
Conclusions:  In addition  to increasing  stem  cell  mobilization  and homing  to ischemic  myocardium,  G-CSF
treatment  after  myocardial  ischemia  improves  survival  by accelerating  neovascularization  and  reducing
apoptosis.
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Granulocyte colony stimulating factor (G-CSF), which can mobi-
ize movement of multipotential bone marrow (BM) progenitor
ells into peripheral blood [1],  may  improve post-myocardial
nfarction (MI) left ventricular (LV) remodeling and function [2].
t present, the main mechanism is believed to be transdifferen-
iation of BM progenitor cells into the cell lineages of the heart,
ncluding cardiomyocytes and endothelial cells in the MI  tissues
3]. However, studies have suggested that the transdifferentiation
f c-Kit-positive BM cells into cardiomyocytes is controversial [4]
nd the number of transdifferentiated cardiomyocytes that arise
rom BM stem cells may  be too low to explain improvement in
ardiac remodeling and function [5].
∗ Corresponding author. Tel.: +86 02985324043; fax: +86 02985323709.
E-mail address: zhaoqingbin05@163.com (Q. Zhao).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.09.003anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
Although an earlier report suggested a direct cardioprotective
effect of G-CSF [6],  Harada et al. [7] ﬁrst provided convincing evi-
dence in 2005 that G-CSF acts directly on cardiomyocytes and
promotes their survival after MI  (independent of any BM effects).
Initially, these investigators showed that cardiomyocytes express
G-CSF receptors (G-CSFR), and that ligand binding at the G-CSFR
activates the broadly protective Jak/Stat pathway in cardiomy-
ocytes [7],  and the Akt-endothelial nitric oxide synthase pathway
in whole heart preparations [8].  In rodents subjected to acute MI
this direct cardioprotective effect of G-CSF decreased cardiomy-
ocyte apoptosis, reduced infarct size, increased viable myocardium,
and limited increases in LV end-diastolic pressure [7].
The G-CSFR is expressed by endothelial cells. In vitro, G-CSF
has been shown to directly stimulate the migration and prolifer-
ation of endothelial cells [9],  their repair of mechanically wounded
endothelial monolayers [10], and the formation of capillary tube-
like structures [11]. G-CSF also causes vascular smooth muscle cell
proliferation [12], which may  be important for structural integrity
vier Ltd. All rights reserved.
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n maturing vessels. A direct angiogenic effect, independent of any
M effects, was conﬁrmed in vivo by local G-CSF administration
nto rabbit corneas [10] and ischemic rodent hind limbs [13].
The exact role of G-CSF in the process of myocardial repair fol-
owing injury remains unclear. Furthermore, studies on the use of
-CSF to treat ischemic heart disease currently focus mainly on
I,  the most severe type of coronary heart disease. Therefore, in
his study, we aimed to investigate whether G-CSF treatment in
he early stages is effective in improving survival in a rabbit model
f chronic myocardial ischemia and the underlying mechanisms of
ny beneﬁcial effects.
aterials and methods
nimal care
Japanese white male rabbits (Oryctolagus cuniculus) (age, 2–3
onths; weight, 3–3.5 kg) were housed and studied with approval
rom and according to the guidelines of the Xi’an Jiaotong
niversity Institutional Animal Care and Use Committee. This
nvestigation also conforms to the Guide for the Care and Use of Lab-
ratory Animals published by the US National Institutes of Health
NIH Publication No. 85-23, revised 1996). Allocation of animals to
xperimental groups in this study was randomized.
nimal model
Rabbits were anesthetized intravenously (i.v.) with sodium pen-
othal (50 mg/kg). Anesthesia was maintained by a continuous
nfusion of sodium pentothal (5 mg/kg over 30 min) via catheter
nto the ear vein. Electrodes were ﬁxed to the right upper extremity,
ight lower extremity, and left lower extremity to obtain readings
sing a Maclab (GE Healthcare, UK) physiological recorder.
The heart was exposed via a center thoracotomy and suspended
n a pericardial cradle with care to avoid damage to the pleura. Par-
ial ligation of the left anterior descending (LAD) coronary artery
as achieved using a 5-0 suture (polydioxanone, Ethicon, New
ersey, USA) passed around the ﬁrst large marginal branch of the
ircumﬂex artery. In sham operated animals, the suture was passed
ut not ligated. Myocardial ischemia was conﬁrmed by the appear-
nce of a regional color thin and a marked lower S-T segment and
 wave inversion on the Maclab recorder. After ﬂushing the tho-
acic cavity with 0.9% saline and placement of the drainage strip,
he chest was closed. Twenty-four hours post-surgery, the drainage
trip was removed and penicillin (800,000 U/day) was  adminis-
ered by intramuscular injection for 5 days.
ytokine treatment
Following surgery, rabbits (n = 132) were randomized into two
roups. The G-CSF treatment group (n = 52) was injected subcuta-
eously with recombinant human G-CSF at 10 g/kg daily (Kirin
rewery, Tokyo, Japan). Twenty of these rabbits were used for sur-
ival analysis and 32 for tissue sampling. The control group (n = 80)
as injected subcutaneously with an equivalent volume of saline,
eginning at 1 h after surgery and continuing daily for 6 days.
wenty of these rabbits were used for survival analysis and 60 for
issue sampling.
urvival studyThis study was designed to determine the 28-day survival of
abbits after myocardial ischemia. Following surgery, 40 rabbits
ere allocated at random into the G-CSF treatment group (n = 20)iology 61 (2013) 87–94
and the control group (n = 20). All-cause mortality was the primary
end point of this study.
Post-surgical sampling
At 1, 3, 7, or 28 days post-surgery, animals were anes-
thetized with sodium pentothal (50 mg/kg i.v.), tracheotomized,
and mechanically ventilated. Using the thoracotomy method, the
heart was removed quickly. The ischemic myocardium was  divided
into two equal portions, with one portion ﬁxed in 4% citromint for
pathological evaluation, and the other placed into liquid nitrogen
for real-time polymerase chain reaction (PCR) analysis.
Detection of stem cells
Peripheral blood CD34+ cells were used as an indicator of the
presence of hematopoietic stem cells. The percentage of CD34+ cells
in peripheral blood samples at 1, 3, 7, and 28 days post-surgery
(n = 6) was determined using ﬂow cytometry. Brieﬂy, peripheral
blood samples collected at the indicated times were stained within
24 h with a phycoerythrin (PE)-conjugated anti-CD34 monoclonal
antibody (Becton-Dickinson, USA). For negative controls, cells were
stained with PE-conjugated mouse IgG1 (Becton-Dickinson, USA).
Samples were subjected to automated data acquisition and anal-
ysis using the BD Procount software for ﬂow cytometry (FACS
CabiburTM, Becton-Dickinson, USA).
Immunohistochemistry
The presence of von Willebrand factor (vWF) and CD34+ cells
in ischemic myocardium was assessed by immunohistochemical
staining. Parafﬁn-embedded post-surgical sampling tissue was sec-
tioned (5 m)  and mounted on positively charged slides. Sections
were deparafﬁnized and hydrated in graded alcohol to distilled
water. They were then subjected to heat-induced epitope retrieval
by immersion in 0.01 M sodium citrate buffer (pH 6.0), heated under
15 pounds per square inch (psi) in a pressure cooker (Presto, 4 quart,
USA) for 9 min, and allowed to cool for approximately 10 min before
removal from the cooker. Endogenous peroxidase was inactivated
with hydrogen peroxide.
Specimens were incubated with 1:100 dilutions [phosphate-
buffered saline (PBS) pH 7.4] of antibodies (Santa Cruz Biotechnol-
ogy, USA) against vWF  or CD34 overnight at 4 ◦C. They were then
washed and incubated with their corresponding secondary anti-
body conjugated to biotin for 20 min  and rinsed in buffer (PBS, pH
7.4). The sections were counterstained with hematoxylin, rinsed
and coverslipped. The immunocomplex was visualized with di-
aminobenzidine (DAB). For negative immunostaining controls, the
primary antibody was replaced with PBS. Microscopic analysis was
performed under high-power magniﬁcation (40×) and the mean
number of positively stained cells was determined across ﬁve ran-
dom ﬁelds.
Detection of apoptosis using TUNEL staining
The terminal dUTP nick end-labeling (TUNEL) assay detects
nuclear DNA fragmentation as a measure of cellular apoptosis. This
assay was used to measure the level of apoptosis in myocardial tis-
sue harvested from surgically treated animals undergoing G-CSF
and placebo administration. The TUNEL assay was performed on
parafﬁn-embedded tissue samples using the DeadEndTM Fluoro-
metric TUNEL System (Promega, Wisconsin, USA) according to the
instructions provided by the manufacturer. Brieﬂy, samples were
incubated in 2% hydrogen peroxide, rinsed three times in PBS and
pretreated with 0.25% trypsin for 10 min. After three rinses in PBS,
slides were incubated for 1 h at 37 ◦C in a moist chamber with
Q. Zhao et al. / Journal of Cardiology 61 (2013) 87–94 89
Table  1
Primers used for quantitative reverse transcriptase polymerase chain reaction.
Target gene Upstream
primer (5′–3′)
Downstream
primer (5′–3′)
Vascular endothelial GGCAGAAGAAGGAGA CAG AGG CAC
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Fig. 1. Kaplan–Meier curve showing survival after myocardial ischemia in rabbits
administered with granulocyte colony stimulating factor (G-CSF) and control rabbits
(n  = 20 per group). Mortality at 28 days was signiﬁcantly reduced in the G-CSF group
(p  = 0.0348).
Fig. 2. Percentage of CD34+ cells in peripheral blood at different time-points post-growth factor CAA TAA ACC GCA GGA AGG
-Actin CCATCTACGAGGGCTACGC CGG CTG TGG
TCA CGA AGG
he TUNEL mixture (5 l TdT + 45 l ﬂuorescein-conjugated dUTP).
fter three rinses in PBS, the slides were incubated with 50 l per-
xidase for 30 min  at 37 ◦C. After three rinses in PBS, DAB was
pplied to the samples. For each assay, a negative control was  per-
ormed on one sample with the omission of TdT. The slides were
isualized by reﬂected light microscope (Olympus, Tokyo, Japan).
he cardiomyocyte apoptotic index was calculated by counting
he number of TUNEL-positive cells per 1000 cardiomyocytes. This
valuation was carried out by two independent operators in a
linded manner.
eal-time quantitative PCR analysis
Total RNA was extracted from the ischemic myocardium tis-
ue stored in liquid nitrogen, using TRIzol reagent (Invitrogen,
alifornia, USA) according to the instructions provided by the
anufacturer. cDNA was  synthesized using the ImProm-II Reverse
ranscription System (Promega) according to the instructions pro-
ided by the manufacturer. Expression of vascular endothelial
rowth factor (VEGF) mRNA was measured by real-time reverse
ranscriptase (RT)-PCR ampliﬁcation using SYBR ExScriptTM RT-PCR
it (TaKaRa, Dalian, China) and detected in a Bio-Rad iQ5 Real-
ime Cycler instrument (California, USA). Primers (Table 1) were
esigned using Primer Premiere software (Premiere Biosoft, Palo
lto, CA, USA). Samples were analyzed in duplicate and normal-
zed to -actin expression. The ampliﬁcation protocol included an
nitial denaturation at 95 ◦C for 10 s followed by 40 cycles of 95 ◦C
or 5 s, 57 ◦C for 15 s, and 72 ◦C for 10 s. All real-time RT-PCR prod-
cts were visualized by 4% agarose gel electrophoresis and stained
ith ethidium bromide to conﬁrm the correct amplicon size. Reac-
ion efﬁciencies were determined with 10-fold serial dilutions of
uriﬁed PCR products, using the slope of the graph of threshold
ycle (Ct) vs. dilution of the sample. The fold-change in expression
F) of each target mRNA relative to -actin was calculated under
xperimental and control conditions based on Ct as:
 = 2−Ct, where Ct = Cttarget − Ct-actin
and Ct = Ctexperimental − Ctcontrol.
tatistical analysis
The data collected for the percentage of CD34+ cells, numbers of
D34+ cells, numbers of vessels, apoptotic index, and fold-change
f VEGF mRNA expression were expressed as the mean ± standard
eviation. Inter-group comparisons were analyzed by two-way
NOVA and LSD t-tests using GraphPad Prism version 4.00 soft-
are (San Diego, CA, USA). Differences were considered statistically
igniﬁcant at p < 0.05. The rates of all-cause mortality were calcu-
ated using Kaplan–Meier survival curves and compared using the
og-rank test.
esultsurvival analysis
Improved survival with G-CSF therapy was observed in rabbits
ith myocardial ischemia compared with the control group (75%left anterior descending artery (LAD) ligation in granulocyte colony stimulating
factor (G-CSF)-treated and control rabbits determined by ﬂow cytometry (n = 6;
*p  < 0.01).
vs. 40%, respectively; p = 0.0348). In the G-CSF intervention group
(n = 20), the survival rate after 28 days of follow-up was 75%; 5
rabbits in the experimental group died, 4 from heart failure and
1 from ventricular arrhythmias; in the control group (n = 20), 12
rabbits died after 28 days of follow-up and the survival rate was
40%; among these, 10 rabbits died of heart failure and 2 died of
ventricular arrhythmia. Kaplan–Meier analysis revealed that G-CSF
increased survival 28 days after myocardial ischemia in rabbits
(Fig. 1).
Peripheral CD34+ cells
In animals receiving G-CSF treatment, the percentage of CD34+
cells circulating in peripheral blood on days 1, 3, 7, and 28
post-surgery was  signiﬁcantly higher than that measured in the
corresponding control group (n = 6, p < 0.01). On day 7 after surgery,
the percentage of CD34+ cells in both groups was statistically sig-
niﬁcantly higher than at other time-points (p < 0.01) (Fig. 2).
Immunohistochemical analysis
Endothelial cells were identiﬁed immunohistochemically using
anti-vWF antibody. The numbers of vWF-positive vessels in
ischemic regions were counted in ﬁve randomly selected ﬁelds per
sample (n = 6, per group). On day 28 post-surgery, the G-CSF group
had signiﬁcantly greater numbers of vWF-positive vessels than
the control group [16.2 ± 5.6/mm2 (control) vs. 33.6 ± 10.4/mm2
(G-CSF), p < 0.01; Fig. 3]. Immunohistochemical detection of the
90 Q. Zhao et al. / Journal of Cardiology 61 (2013) 87–94
Fig. 3. Representative photographs of the von Willebrand factor (vWF)-stained sections of the (A) control and (B) granulocyte colony stimulating factor (G-CSF)-treated
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resence of CD34+ cells in ischemic myocardium showed that the
umber of CD34+ cells was signiﬁcantly greater in the G-CSF group
han that observed in the corresponding tissue from control ani-
als on day 7 post-surgery. Levels declined to those observed in
ontrol animals by day 28 post-surgery (Fig. 4).
uantitation of VEGF mRNA expression
Real-time PCR analysis showed that there was no difference in
EGF mRNA levels in ischemic tissue on day 1 following surgery
etween the G-CSF and control groups (n = 6, per group). How-
ver, VEGF mRNA levels in ischemic myocardium were signiﬁcantly
igher in the G-CSF group than that in the control group (p < 0.01)
n days 3, 7, and 28 post-surgery (Fig. 5).
UNEL analysis of apoptosis
Apoptosis levels in myocardium were assessed at day 7 and
ay 28 post-surgery in both groups. TUNEL-positive nuclei were
bserved in cardiomyocytes from tissue samples of operated ani-
als that were administered either G-CSF or placebo. The apoptotic
ndex (number of TUNEL-positive cells per 1000 myocytes) in
schemic myocardium was signiﬁcantly lower in the G-CSF group
ompared with the control group (3.6 ± 1.4 vs. 6.5 ± 1.6) on day
8 post-surgery (n = 6 per group, Fig. 6). On day 7 post-surgery,
here was no signiﬁcant difference in the apoptotic index between
-CSF-treated and control animals.y (n = 6; *p < 0.05). LAD, left anterior descending artery. Scale bar represents 20 m.
Discussion
The present study revealed that G-CSF improved survival of
rabbits with myocardial ischemia and investigated stem cell mobi-
lization and homing, neovascularization, expression of VEGF, and
apoptosis index in order to elucidate the mechanism underlying
this effect.
Many investigators have administered G-CSF at the time of MI
– often commencing a few hours post-MI but occasionally com-
mencing prior to MI  – and then continued this therapy for several
days. In small animals (mice [7,14],  rats [15], and rabbits [16]),
these studies demonstrated that G-CSF improves measures of LV
performance and recovery, resulting in reduced infarct size [7]
with better preservation of infarct wall thickness [17], increased
LV mean [18] and developed pressures [19], lower LV end-diastolic
pressure [7,14,15,17], reduced LV end-diastolic [7,15,16] and end-
systolic [20] diameter and/or volume, increased LV contractility
(+dP/dt) [15] and relaxation (−dP/dt) [18], increased LV ejection
fraction (LVEF) [21], and increased cardiac output [22]. Moreover,
survival was frequently improved by G-CSF [16].
Harada et al. [7] showed that cardiomyocytes express G-
CSFRs, and that ligand binding at the G-CSFR activates the
broadly protective Jak/Stat pathway in cardiomyocytes [7],  and
the Akt-endothelial nitric oxide synthase pathway in whole heart
preparations [8]. In rodents subjected to acute-MI this direct car-
dioprotective effect of G-CSF decreased cardiomyocyte apoptosis,
reduced infarct size, increased viable myocardium, and limited
increases in LV end-diastolic pressure [7]. These investigators then
Q. Zhao et al. / Journal of Cardiology 61 (2013) 87–94 91
Fig. 4. Representative photographs of the CD34-stained sections of the (A) control and (B) granulocyte colony stimulating factor (G-CSF)-treated groups at day 28 post-
surgery. (C) Numbers of CD34+ cells in ischemic myocardium at different time-points wer
represents 20 m.
Fig. 5. Fold-change in vascular endothelial growth factor (VEGF) mRNA expression
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devels in ischemic myocardium of the control and granulocyte colony stimulating
actor (G-CSF) groups at different time-points (n = 6; *p < 0.01). LAD, left anterior
escending artery.
sed an experimental model that involved isolating ex vivo per-
used rat hearts subjected to ischemia–reperfusion injury in which
here can be no BM effect. They further conﬁrmed that G-CSF exerts
irect cardioprotective effects, decreases cardiac injury, and atten-
ates decreases in ventricular performance. Kuhlmann et al. [22]
emonstrated enhanced cardiomyocyte expression of the G-CSFR
n the ﬁrst weeks after MI,  indicating a potential sensitization of the
eart to the direct effects of G-CSF during this period. Direct car-
ioprotective action of G-CSF has also been reported in a hamstere counted manually (n = 6; *p < 0.01). LAD, left anterior descending artery. Scale bar
model of dilated cardiomyopathy [2]. This animal model develops
cardiomyopathy due to autophagic cardiomyocyte death, which
is a process characterized by the sequestration and degradation
of intracellular components by lysosomal vacuoles. Although the
same cardioprotective pathways (Jak/Stat) were activated in this
model [2],  in contrast to the acute-MI model [7],  G-CSF did not pro-
tect against apoptosis. Rather, G-CSF protected against autophagic
cellular degeneration [2],  signiﬁcantly attenuating the anatomical
and functional progression of cardiomyopathy in these animals.
Apoptosis plays an important role in cardiovascular diseases
such as ischemic heart disease, atherosclerosis, and congestive
heart failure [23]. Our results showed that G-CSF reduced the cell
apoptosis in the ischemic myocardium. This ﬁnding correlates well
with previous studies, providing further evidence that G-CSF exerts
anti-apoptotic functions in myocardial injury.
In this study, G-CSF caused an increased percentage of CD34+
cells circulating in peripheral blood during the early stages of
myocardial ischemia and the presence of CD34+ cells in ischemic
heart tissue. These observations indicate that stem cell mobilization
from the BM and homing to ischemic myocardium occurs as part
of a cardioprotection mechanism of G-CSF. Apart from neutrophils,
G-CSF mobilizes a range of erythroid, megakaryocytic, lymphoid,
and endothelial progenitor populations (which generally do not
express the G-CSFR) from the BM [24]. The pathways involved are
controversial, but ultimately they appear to converge at the dis-
ruption of key cellular anchors within the BM-microenvironment,
one of the most critical being the CXCR4/SDF-1 complex [25],
but which also includes vascular endothelial-cadherin [26]. Cells
characteristically expressing CXCR4 include hematopoietic stem
92 Q. Zhao et al. / Journal of Cardiology 61 (2013) 87–94
Fig. 6. Terminal dUTP nick end-labeling (TUNEL) analysis of formalin-ﬁxed, parafﬁn-embedded myocardium from (A) control animals and (B) granulocyte colony stimulating
factor  (G-CSF)-treated animals at day 28 post-surgery. The brown, TUNEL-positive nuclei (indicated by arrows) are seen among ischemic myocytes (C). The cardiomyocyte
apoptosis index (number of TUNEL-positive cells per 1000 cardiomyocytes) was signiﬁcantly lower in the G-CSF-treated group than in the control group at day 28 post-
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n  this ﬁgure legend, the reader is referred to the web  version of the article.)
ells [27], endothelial progenitor cells (EPCs) [28], and a sub-
et of mesenchymal stem cells [29]. The chemokine SDF-1 (also
nown as CXCL12) is expressed by cells that tether CXCR4-
ositive cells within the BM,  including osteoblasts and some BM
ndothelial cells [30]. Disruption of this anchoring complex per-
its progenitor cells to exit the BM and enter the peripheral
irculation. G-CSF can disrupt the CXCR4/SDF-1 complex by sev-
ral mechanisms. The ﬁrst involves the release of proteases from
-CSFR bearing neutrophils, most notably neutrophil-elastase,
athepsin-G, and matrix-metalloproteinase-9 [27,31], which then
egrade and disrupt CXCR4/SDF-1 interactions. A second mecha-
ism whereby G-CSF disrupts these anchoring complexes involves
ecreased expression of both SDF-1 [30] and CXCR4 [32] by tether-
ng (osteoblast) and progenitor cells respectively. The decrease in
XCR4 is probably due to altered synthesis [33] and/or membrane
xpression on progenitor cells [32,33], whereas the decrease in
DF-1 is predominantly due to a decrease in the absolute number of
M osteoblasts (with little change in SDF-1 membrane expression
n individual osteoblasts) [30]. Hypoxia also regulates CXCR4/SDF-
 signaling and augments the CXCR4/SDF-1 axis by enhancing
xpression of both CXCR4 by progenitor cells [34] and SDF-1 in
schemic tissues [35].
In our rabbit model of myocardial ischemia, G-CSF promoted
eovascularization and increased VEGF mRNA levels in myocardial
issue over 7 days following the injury. Our results closely correlate
ith previous studies, providing further evidence that G-CSF plays
 role in angiogenesis after myocardial injury.g artery. Scale bar represents 20 m.  (For interpretation of the references to color
G-CSF has also been shown to recruit VEGF-expressing neu-
trophils to ischemic tissues and to increase local and systemic
VEGF levels [36]. That G-CSF/granulocyte macrophage colony stim-
ulating factor might mediate angiogenesis by activating paracrine
pathways is consistent with other work showing that progenitor
cells and/or EPCs may  mediate angiogenesis by the elaboration and
local secretion of angiogenic cytokines (such as VEGF), rather than
by direct structural incorporation into newly forming vessels [37].
Evidence for cardiac angiogenesis mediated by G-CSF comes from
studies of both small [18] and large [38] animal models of MI.  These
studies showed that G-CSF administration, generally commenced
within 24 h of acute-MI, increases peri-infarct neovascularization
and decreases endothelial cell apoptosis. In addition to a direct
action, G-CSF may  further augment neovascularization in vivo by
facilitating the recruitment of circulating leukocytes, EPCs [18],
and CXCR4+ cells [39]. This effect results from G-CSF-mediated
increases in intracellular adhesion molecule-1 [18] and SDF-1 [39]
expression in damaged or ischemic cardiac tissue. G-CSF mobiliza-
tion of stem cells includes EPCs in addition to hematopoietic stem
cells. EPCs can differentiate into vascular endothelial cells at the site
of MI  to form the new blood vessels. Kocher et al. [40] intravenously
injected G-CSF mobilized BM stem cell into the nude mice sub-
jected to acute MI  and showed that neovascularization signiﬁcantly
increased at the site of the MI.  Furthermore, the LV ejection fraction
in the treatment group was higher than that of the non-treatment
group, indicating that G-CSF promotes MI  angiogenesis and pro-
liferation, to improve heart function. Orlic et al. [41] also found
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bserved that the small arteries (diameter, 10–30 m thick) were
omposed of several layers of smooth muscle cells and communi-
ated with the coronary artery, while these blood vessels improved
he blood supply to the myocardial tissue.
In this study, we have demonstrated that early administration
f G-CSF improves survival in an animal model of chronic myocar-
ial ischemia. Further investigation revealed that BM stem cell
obilization and homing to the ischemic myocardial tissue, neo-
ascularization, increased VEGF expression, and reduced apoptosis
re involved in the mechanisms of improving survival of post-MI
abbits. Therefore, a window of opportunity may exist in the early
tages of ischemic heart disease in which G-CSF therapy can be
ffective.
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